Medifast, Inc. Announces Third Quarter 2018 Financial Results

Go back to Medifast, Inc. Announces Third Quarter 2018 Financial Results

Medifast (MED) Defended at DA Davidson

November 7, 2018 9:53 AM EST

DA Davidson analyst Linda Bolton Weiser reiterated a Buy rating and $249 price target on Medifast (NYSE: MED) telling clients to buy on today's pull-back.

Weiser commented, "MED reported 3Q18 sales of $139M, above consensus of $125M and guidance of $120M-$125M. Revenue growth... More

Medifast (MED) Reports In-Line Q3 EPS, Offers Guidance

November 6, 2018 4:13 PM EST

Medifast (NYSE: MED) reported Q3 EPS of $1.14, in-line with the analyst estimate of $1.14. Revenue for the quarter came in at $139.2 million versus the consensus estimate of $125.81 million.

GUIDANCE:

Medifast sees Q4 2018 EPS of $1.15-$1.20, versus the consensus of $1.16. Medifast sees Q4 2018... More